SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Reports Significant Revenue Growth and Gross Margin Expansion in 2025

COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the year ended December 31, 2025.

2025 Financial Highlights Compared to 2024:

• Net revenue increased 216% to $431,609 from $136,643
• Gross Margin Expanded by 7,240 Basis Points to 76.8%
• Excluding a one-time, non-cash impairment charge of $26.3 million, net loss from continuing operations improved by approximately $37,000 year-over-year
• As of December 31, 2025, the company had cash and cash equivalents of approximately $6.7 million and positive working capital of approximately $5.2 million

Key Operational Highlights in 2025 and Subsequent Events:

• Secured multiple PBM-led GPO rebate agreements, supporting expanded commercial coverage and formulary placement for Arbli™
• Executed institutional GPO agreements, expanding U.S. access to more than 2,500 healthcare institutions nationwide for Arbli™
• Achieved formulary inclusion with major national health plans for Arbli™, extending coverage to over 100 million lives
• Received an Orange Book-listable patent for Arbli™ (losartan potassium) Oral Suspension, 10mg/mL, the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market for treating hypertension, reinforcing and expanding Scienture’s intellectual property position
• Established a strategic collaboration with BlinkRx for Arbli™ to enhance patient access, fulfillment, and adherence through an integrated digital pharmacy and hub services platform
• Received an Orange Book-listable patent for REZENOPY™ (naloxone HCl) nasal spray 10 mg, the highest-dose FDA-approved naloxone HCl nasal spray for emergency opioid overdose treatment
• Formalized multiple commercial GPO agreements for REZENOPY™, expanding access to over 5,000 healthcare institutions and reaching approximately 60% of the U.S. institutional market, including first responders, EMS providers, and rehabilitation centers

Management Commentary

Narasimhan Mani, President and Co-CEO of Scienture, commented, “2025 was a transformational year for Scienture, highlighted by the successful launch of Arbli™ and strong early commercial traction in the approximately $241 million U.S. losartan market, representing 72 million prescriptions annually (IQVIA MAT December 2025). We delivered 216% revenue growth, significant gross margin expansion to 76.8%, and improved operating efficiency, while maintaining a solid balance sheet with $6.7 million in cash and positive working capital. Excluding a one-time, non-cash impairment charge, our net loss from continuing operations improved year over year, reflecting the underlying progress of the business.”

“We believe 2026 will reflect the momentum we’ve built across prescriber adoption, distribution, and patient demand for Arbli™, while also positioning us for the planned commercial launch of REZENOPY™ in the second quarter of 2026,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “Our recently formalized GPO agreements for REZENOPY™ represent a meaningful step forward in expanding our institutional reach, providing access to more than 5,000 healthcare facilities and approximately 60% of the U.S. institutional market. With a U.S. naloxone market of approximately $141 million in annual sales and approximately 9.4 million prescription units, we believe REZENOPY™, as the highest-dose FDA-approved naloxone nasal spray, is well positioned to drive broader adoption and capture market share as we continue executing our commercialization strategy. In parallel, we are actively evaluating additional acquisition opportunities to further expand our product portfolio and drive long-term growth.”

2025 Financial Summary

Revenue for the year ended December 31, 2025 increased 216% to $431,609, compared to $136,643 in 2024, driven by initial sales of Arbli™ following its FDA approval and commercial launch in the third quarter of 2025. Full-year revenue reflects conservative adjustments for rebates and discounts, which are expected to stabilize as the product gains traction. Gross profit increased to $331,482 in 2025 compared to $6,005 in 2024, with gross margin increasing to 76.8%, compared to 4.4% in 2024, reflecting the transition to higher-margin branded pharmaceutical sales from prior lower-margin wholesale activity.

Total operating expenses were $42.9 million, primarily driven by a one-time, non-cash impairment charge of $26.3 million. Excluding these charges, operating expenses were $16.6 million, compared to $14.7 million in 2024. Net loss from continuing operations was $41.5 million, largely attributable to the non-cash impairment. Excluding this one-time charge, net loss improved by $37,000 year-over-year.

As of December 31, 2025, the company had approximately $6.7 million in cash and cash equivalents and approximately $5.2 million in positive working capital.

About Arbli™

Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.

INDICATION

Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:

• Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
• Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
• Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

IMPORTANT SAFETY INFORMATION

• Do not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
• Do not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli™ in patients with renal impairment (GFR